1-10 of 10
David J Andorsky
Close
Sort by
Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David J Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Yingxue Chen, Jade Chen, Rajat Bannerji, Apoorva Kapopara, Attila Szanto, Franck Morschhauser
Journal: Blood
Blood (2023) 142 (Supplement 1): 3035.
https://doi.org/10.1182/blood-2023-179910
Published: 2023
Journal Articles

Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting

David J Andorsky, Ira Zackon, Thomas W Wilson, Kathleen M Aguilar, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A Maglinte
Journal: Blood
Blood (2023) 142 (Supplement 1): 2413.
https://doi.org/10.1182/blood-2023-172880
Published: 2023
Journal Articles

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Jeff P. Sharman, Ralph V. Boccia, Thomas Doerr, Kristin Conte, Yang Bai, Brian Elliott, David J. Andorsky
Journal: Blood
Blood (2022) 140 (Supplement 1): 9491–9492.
https://doi.org/10.1182/blood-2022-157575
Published: 2022
Journal Articles

Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study

Jeff Sharman, MD, Shaum Kabadi, PhD MPH, Jamyia Clark, MPH, E Susan Amirian, PhD MS, David J. Andorsky, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4163.
https://doi.org/10.1182/blood-2018-99-118848
Published: 2018
Journal Articles

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Gilles Andre Salles, Wojciech Jurczak, David J. Andorsky, MD, Donald P. Quick, MD, Jack W. Singer, MD, Simran Bedi Singh, Lixia Wang, PhD, Anton Egorov, MD, Christine Gabarroca, MSc, Ruth Pettengell, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4189.
https://doi.org/10.1182/blood-2018-99-112455
Published: 2018
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD, Fontanet Bijou, MD, Vincent Ribrag, MD, Julio C. Chavez, MD, Thomas E. Witzig, MD, David J. Andorsky, MD, Leonard M. Klein, MD, Daniel Greenwald, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Shailaja Uttamsingh, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Tianlei Chen, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2018-99-114409
Published: 2018
Journal Articles

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

David J. Andorsky, MD, Abdulraheem Yacoub, MD, Jacob D. Bitran, MD, Jason Melear, MD, Heather D. Brooks, MD BS, BA, Kenneth A. Foon, MD, Syed Rizvi, MD, Mary Llorente, Jiahui Li, PhD, Jeff P. Sharman, MD
Journal: Blood
Blood (2016) 128 (22): 1798.
https://doi.org/10.1182/blood.V128.22.1798.1798
Published: 2016
Journal Articles

Spectrum of Expression and Biological Activity of Programmed Death Ligand 1 (PD-L1) in Non-Hodgkin’s Lymphomas

David J Andorsky, MD, Reiko Yamada, Kristopher K Steward, BS, Sven De Vos, MD, PhD, Jonathan Said, John M Timmerman, MD
Journal: Blood
Blood (2008) 112 (11): 4140.
https://doi.org/10.1182/blood.V112.11.4140.4140
Published: 2008
Journal Articles

Recombinant Interleukin-21 Plus Rituximab: Clinical Activity in a Phase 1, Dose-Finding Trial in Relapsed Low-Grade B Cell Lymphoma.

John M. Timmerman, MD, John C. Byrd, MD, David J. Andorsky, MD, Muriel F. Siadak, PA-C, Todd DeVries, PhD, Diana F. Hausman, MD, John M. Pagel, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2577.
https://doi.org/10.1182/blood.V110.11.2577.2577
Published: 2007
Journal Articles

Baseline Physical and Mental Functioning Are Strong Predictors of Post-Stem Cell Transplant Function and Quality of Life.

David J. Andorsky, MD, Stephanie J. Lee, MD, MPH
Journal: Blood
Blood (2004) 104 (11): 3322.
https://doi.org/10.1182/blood.V104.11.3322.3322
Published: 2004